Life expectancy in heart failure needs to be patient-specific, with a current four-year mortality rate of 50% in patients with heart failure and a one-year mortality rate of up to 50% in patients with severe heart failure. Survival rates are population-specific descriptions, and cardiac function needs to be evaluated for individual patient survival prognosis. Currently, the six-minute walk test is simple and easy to perform to evaluate the severity and efficacy of heart failure by assessing exercise tolerance in patients with chronic heart failure. The experiment requires that the patient walks as quickly as possible in a flat corridor, and the six-minute walking distance is measured, <150m for severe heart failure, 150-450m for moderate heart failure, >450m for mild heart failure. The description of heart failure is mainly based on the left ventricular ejection fraction (LVEF).LVEF<40% is called reduced ejection fraction heart failure, i.e. systolic heart failure.LVEFâ„50% is called preserved ejection fraction heart failure, i.e. diastolic heart failure. BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal B-type natriuretic peptide precursor) are commonly used clinically for the diagnosis of heart failure, and for risk assessment of clinical events. High levels of natriuretic peptide in treated patients suggest a poor prognosis, but elevated natriuretic peptide can be caused by pulmonary artery embolism, tachycardia, myocardial ischemia, renal insufficiency, cirrhosis, and so on, and is therefore not very specific. If heart failure is diagnosed, it should be treated actively to prevent and delay the development of heart failure, relieve clinical symptoms, improve the quality of life, and reduce the death rate.